Drägerwerk AG & Co. KGaA stock
DRW3.DEXETRAHealthcareISIN DE0005550636WKN 555063
66Score 66 out of 100, Neutral
Price and trend
83 / 100
Price history
+62% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since January 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 67).
The price is 11% below its 52-week high. Largest decline in 20 years: 82% (May 2007 to March 2009).
Chart figures for advanced users
- SMA 50$121.83
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$107.75
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)67
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$74.24
- The lowest closing price of the last twelve months.
- Resistance$138.07
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Drägerwerk AG & Co. KGaA belongs to the Medical (Devices) industry (Germany) and, with a market value of $2.31B, is number 38 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.86B (up 3.3% year on year) and earnings of $154.58M (up 12.1%).
- For fiscal 2026, analysts expect on average revenue of $4.01B (up 3.9%) and adjusted earnings per share of $9.27 (up 12.8%).
Show more
- MEQIRI Score 66 out of 100 (Neutral): rank 194 of 702 in Healthcare, median 53.
- The P/E is 12.3 (Medical (Devices) median 29.1, own median of recent years 9.3).
- Our model puts fair value at $271.55, with the price 55% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 134% of earnings over the last 12 months.Fundamentals 79
- More cash than debtCash $300.18M, financial debt $253.68M.Stability 80
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are valuation and technical analysis, while growth holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 65 to 66.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
What lowers it
- solid fundamentals
- low growth grade (crashed less often in the backtest)
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $193.96 and expensive above $452.58 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $251.99 (cash-flow model) and $291.10 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $249.88, at 6.1% it would be $304.11.
Possible value trap: looks cheap, but weak growth.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 5.1% on the twelve months before. Revenue has grown solidly since 2006, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 44%, operating 7%, net 4%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 17 Mar 2027in 124 days
- Last reported
- 29 Oct 2026EPS reported $2.02
Analyst estimates
- Earnings per share
- $9.27−7.2%
- Revenue
- $4.01B−0.3%
- Earnings per share
- $9.88−2.5%
- Revenue
- $4.18B−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −2.5%Drägerwerk confirmed its full-year guidance of 2% to 6% sales growth and a 6% to 8% EBIT margin, only the net debt guidance was slightly adjusted.
“We continue to expect net sales growth of 2% to 6%, net of currency effects and an EBIT margin of 6% to 8% for the full year of 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
What happened at Drägerwerk AG & Co. KGaA
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 66
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- iRhythm TechnologiesIRTC $3.1B30
- GN Store NordGN.CO $2.63B55
- NeogenNEOG $2.44B41
- UFP TechnologiesUFPT $2.37B76
- ElektaEKTA-B.ST $2.27B56
- Establishment Labs HoldingsESTA $2.05B41
- Butterfly NetworkBFLY $1.78B45
- Embla Medical hf.EMBLA.CO $1.76B67
ETFs that hold Drägerwerk AG & Co. KGaA
Held by 17 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi SDAX UCITS ETF DistC005 | 2.30% | 0.70% | €158.8M |
| Amundi TecDAX UCITS ETF DistE908 | 0.74% | 0.40% | €85.66M |
| UBS MSCI EMU Small Cap UCITS ETF EUR disUEFD | 0.17% | 0.28% | €630.46M |
Show 5 more
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.11% | 0.30% | €813.64M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.07% | 0.30% | €3.45B |
| Vanguard Germany All Cap UCITS ETF (EUR) DistributingVGER | 0.06% | 0.07% | €255.26M |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.06% | 0.40% | €580.62M |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.03% | 0.34% | €16.96M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.